| 1.4 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.75 | 1-year : | 2.04 |
| Resists | First : | 1.5 | Second : | 1.75 |
| Pivot price | 1.32  |
|||
| Supports | First : | 1.28 | Second : | 1.15 |
| MAs | MA(5) : | 1.4 |
MA(20) : | 1.3 |
| MA(100) : | 1.45 |
MA(250) : | 1.94 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 91.3 |
D(3) : | 92.4 |
| RSI | RSI(14): 57.7 | |||
| 52-week | High : | 3.2 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BCDA ] has closed below upper band by 23.9%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.42 |
| Low: | 1.33 - 1.34 | 1.34 - 1.35 |
| Close: | 1.39 - 1.4 | 1.4 - 1.41 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Tue, 16 Dec 2025
BioCardia (NASDAQ: BCDA) allowed to advance to formal PMDA consultation on CardiAMP HFrEF - Stock Titan
Tue, 16 Dec 2025
BioCardia Advances CardiAMP Therapy in Japan - TipRanks
Mon, 01 Dec 2025
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - GlobeNewswire
Wed, 12 Nov 2025
BioCardia, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - Quiver Quantitative
Wed, 12 Nov 2025
Earnings call transcript: Biocardia Q3 2025 focuses on heart therapy progress - Investing.com
Tue, 23 Sep 2025
Biocardia director Stertzer buys $498k in shares - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 167 (K) |
| Shares Short P.Month | 175 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.5 % |
| Return on Equity (ttm) | -317.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.5 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.99 |
| PEG Ratio | 0 |
| Price to Book value | 5.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|